RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA
Clinical trials for RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo may boost CAR-T success in tough lymphoma
Disease control Recruiting nowThis study tests whether giving two drugs (loncastuximab tesirine and rituximab) before standard CAR-T cell therapy can improve outcomes for people with relapsed or hard-to-treat large B-cell lymphoma. About 29 adults will receive this bridging treatment to see if it makes the CA…
Matched conditions: RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: University of Utah • Aim: Disease control
Last updated Jun 15, 2026 19:03 UTC
-
New CAR T-Cell therapy KITE-753 takes on standard treatment in lymphoma showdown
Disease control Recruiting nowThis phase 3 study tests whether a new treatment called KITE-753 works better than the current CAR T-cell therapy, axicabtagene ciloleucel, for adults with large B-cell lymphoma that has come back or not responded after initial treatment. About 550 participants will be randomly a…
Matched conditions: RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA
Phase: PHASE3 • Sponsor: Kite, A Gilead Company • Aim: Disease control
Last updated Jun 11, 2026 11:57 UTC